Akari Therapeutics Plc
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025 and 2024
(amounts in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $5,203 | $2,599 |
| Restricted cash | 60 | 60 |
| Prepaid expenses | 185 | 92 |
| Other current assets | 14 | 201 |
| Total current assets | 5,462 | 2,952 |
| Goodwill | 8,430 | 8,430 |
| Other intangible assets | 34,000 | 39,180 |
| Total assets | $47,892 | $50,562 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $8,770 | $12,407 |
| Accrued expenses | 2,342 | 3,137 |
| Convertible notes, net | 673 | 700 |
| Convertible notes, related party | — | 250 |
| Notes payable, net | 81 | 659 |
| Notes payable, related party | — | 1,651 |
| Warrant liabilities | 61 | 1,012 |
| Other current liabilities | 424 | 94 |
| Total current liabilities | 12,351 | 19,910 |
| Derivative liability | 230 | — |
| Other non-current liabilities | 31 | 383 |
| Deferred tax liability | 6,952 | 8,040 |
| Total liabilities | 19,564 | 28,333 |
| Commitments and contingencies (Note 11) | - | - |
| Shareholders’ equity: | ||
| Share capital of $0.000000005 par value | ||
| Authorized: 761,963,201,733 and 245,035,791,523 ordinary shares at December 31, 2025 and December 31, 2024, respectively; issued and outstanding: 90,536,879,533 and 53,186,919,523 ordinary shares at December 31, 2025 and December 31, 2024, respectively | — | 5,319 |
| Additional paid-in capital | 234,318 | 212,706 |
| Capital redemption reserve | 59,342 | 52,194 |
| Accumulated other comprehensive loss | (782) | (738) |
| Accumulated deficit | (264,550) | (247,252) |
| Total shareholders’ equity | 28,328 | 22,229 |
| Total liabilities and shareholders’ equity | $47,892 | $50,562 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.